People

Laboratory members

Photo

Who

Research interests

Oni-Orisan.
Anna Wu

Akinyemi O. Oni-Orisan, PharmD, PhD

Principal investigator

[email protected]

X Profile (formerly Twitter): @Akinyemi_OO

Introduction: Brains and Braggadocio (audio, 50 minutes).

Pronouns: he/him/his

Clinical validation of pharmacogenetic associations for cardiovascular therapies.

coming soon

Chris Dimitropoulos, MS

PharmD student

[email protected]

Pronouns: he/him/his

My research interests are using personalized medicine to improve health outcomes. Some fields I am interested in are Pharmacogenomics and Immunotherapy.

Douglas.

Michael Douglas, MS

Program manager

[email protected]

X Profile (formerly Twitter): @MDouglas_MS

Pronouns: he/him/his

Evaluating the equitable implementation of new technologies in precision medicine for cardiovascular disease, cancer, and pharmacogenomics.

Boxuan "Jeffrey" Fan, BS

Post-baccalaureate researcher

[email protected]

Pronouns: he/him/his

Exploring the application of data science, statistics, and computer science in the biomedical field, currently with an emphasis on pharmacogenomics.

Haldar.

Tanushree Haldar, PhD

Data scientist

[email protected]

Pronouns: she/her/hers

Implementing statistical methods in both local and cloud computing platforms to analyze biomedical data with special emphasis on pharmacogenomics and genetic epidemiology.

Kvale.

Mark Kvale, PhD

Programmer/analyst 

[email protected]

Pronouns: he/him/his

Using statistical genetics and machine learning techniques to analyze data, to infer results in large-scale genetic and genomic experiments, and to develop novel approaches to analysis.

Oluwaseun "Seun" Odusan, BS

Post-baccalaureate researcher

[email protected]

Pronouns: he/him/they/them

Strong interest in researching disparities in cardiovascular disease within underrepresented groups.

Neven Sarhan, PhD

Postdoctoral fellow

email pending

Pronouns: she/her/hers

Applying statistical analysis to identify pharmacogenetic relationships related to cardiovascular therapies.

Soha Shahidi, BS

MS student in Health Data Science

[email protected]

Pronouns: she/her/hers

Applying machine learning techniques and statistical methods to better understand large genomic data sets for precision medicine.

Nanase Toda, BS

PhD student in Pharmaceutical Sciences and Pharmacogenomics

[email protected]

Pronouns: she/her/hers

Developing and evaluating precision medicine tools to optimize the risk and benefit for therapies.

Imani Warren, BS

PhD student in Pharmaceutical Sciences and Pharmacogenomics

[email protected]

Pronouns: she/her/hers

Evaluation of genetic ancestry versus social factors on race/ethnicity-based drug efficacy, safety, and drug response differences.

Alumni

Photo Name, Role, Years   Project Now
Harmon.

Joseph Harmon, BS

Research Associate

2022-2023

Undergraduate Research Assistant

2019-2020

  PlacEbo-controlled, Randomized, patient-Selected Outcomes N-of-1 triaL (PERSONAL-pilot): alpha-blockers for lower urinary tract symptoms PhD student, Scripps Research. 

Janille Miranda, PharmD

Intensive Research Project PharmD student

2021–2023

  Candidate genetic variants of statin-induced myotoxicity. PGY-1 ambulatory care pharmacy resident, Stanford University.
Cayabyab

Mari Cayabyab, PharmD

Clinical Pharmacology and Therapeutics (CPT) postdoctoral fellow

2020–2022

 

Coronary heart disease polygenic risk score and secondary prevention of myocardial infarction.

Abstract/Award: Cayabyab et al. Clin Pharmacol Ther. 2022;111: S63. Jason Morrow Trainee Award winner (2nd-best trainee abstract at the conference).

Clinical pharmacy specialist – pharmacogenomics, University of Pennsylvania.

Siem Tsegay

Summer Student Research Program (SSRP) undergraduate student

2022

  Pilot study to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of tamsulosin deprescribing. Undergraduate student, Macalester College.
Lu

Brian Lu, PharmD

Pharmacogenomics Discovery Project PharmD student

2019–2021

 

Effect of SLCO1B1 T521C on statin-related myotoxicity with use of lovastatin and atorvastatin.

Publication: Lu et al. Clin Pharmacol Ther. 2021 Sep;110(3):733-740. PMID: 34114646.

Clinical pharmacist, Stanford Health Care Tri-Valley

Laura Sun, PharmD

Pharmacogenomics Discovery Project PharmD student

2019–2021

  Effect of SLCO1B1 T521C on statin-related myotoxicity with use of lovastatin and atorvastatin Clinical pharmacist, Winship Emory Midtown

Adeya Wyatt, BS

Summer Research Project undergraduate student

2020

  The impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on inflammatory biomarkers. PhD student, Columbia University, Biomedical Engineering